ReviewJournal of hepatocellular carcinoma2025
Radiation-Induced Liver Injury: An Overview.
Review in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The future is not always uniform: rethinking radiotherapy through spatial fractionation.Nature reviews. Clinical oncology · 2026Review
- Structural and Functional Characteristics of the Liver After Fractionated Local Electron Irradiation and Against the Background of Ascorbic Acid Administration.Journal of personalized medicine · 2026Review
- The role and therapeutic prospects of intercellular communication and RNA mFrontiers in immunology · 2026Review
- Mitochondria-targeting organoselenium theranostic radioprotectors for simultaneous treatment and imaging of radiation-induced liver injury.Theranostics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiation therapy is one of the main methods of tumor treatment, with over 50% of patients opting for it during treatment. The optimal regimen of radiation therapy aims to increase the dose in the target area while decreasing the dose in normal tissue. Radiotherapy for liver tumors has seen significant development in recent years. Despite the technological progress and improved accuracy of radiotherapy, the path of radiation reaching the target area still passes through normal tissues. Although there is tolerance doses as a reference parameter for normal liver exposure in planning, radiation damage still occurs. In addition, when combination of radiation therapy with chemotherapy, targeted therapy and immunotherapy has been widely used in recent years, the occurrence of RILD still affects the implementation of other treatment programs. In this review, latest research results of RILD are discussed to better understand the mechanism and provide research directions for optimizing radiotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.